Abstract: Objective To analyze iodine[¹³¹Ⅰ] metuximab injection combined with TACE treatment in recurrent patients with hepatocellular carcinoma （HCC） after naive TACE treatment. Methods From May 2013 to August 2014,58 patients with recurrent HCC after TACE treatment in our hospital were recruited in this study, and they were randomly divided into observation group and control group with 29 cases in each. The patients in control group were given conventional TACE,and in observation group were given iodine [¹³¹Ⅰ] metuximab injection combined with TACE. The efficacy,laboratory indexes and adverse reactions were compared in the two groups. Results The total effective rates in observation group and control group were 55.17% and 31.03%,respectively（P<0.05）;the serum albumin levels decreased significantly（P<0.05）,and bilirubin levels increased significantly（P<0.05） in the observation group one week after treatment as compared to those before treatment; the serum albumin levels dropped significantly （P<0.05）,and bilirubin levels increased significantly （P<0.05） in the control group too;the incidence of adverse reactions in observation group was 10.34%,and it was 3.45% in the control group;the 1 a survival rate in observation group was 55.17%,and it was 48.27% in the control（Log-rank=5.782,P=0.016）;the mean disease progression times in the observation and control groups were （4.83±4.10） m and （2.54±2.07） m,respectively （P<0.05）. Conclusion Iodine [¹³¹Ⅰ] metuximab injection combined with TACE in treatment of recurrent patients with HCC has a better efficacy than that of TACE alone,and it is safe and feasible.

Key words: Hepatocellular carcinoma, Transarterial chemoembolization, Metuximab, Recurrence, Efficacy